- Home
- TRUE vs ACIU Comparison
TRUE vs ACIU Comparison
Compare TRUE & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TRUE | ACIU |
|---|---|---|
| Founded | 2005 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 196.6M | 213.3M |
| IPO Year | 2014 | 2016 |
Fundamental Metrics
Financial Performance| Metric | TRUE | ACIU |
|---|---|---|
| Price | $2.54 | $3.60 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | $2.55 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 1.6M | 402.0K |
| Earning Date | 02-17-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $181,222,000.00 | $5,482,957.00 |
| Revenue This Year | $9.14 | N/A |
| Revenue Next Year | $7.47 | $644.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.18 | N/A |
| 52 Week Low | $1.05 | $1.43 |
| 52 Week High | $3.83 | $4.00 |
Technical Indicators
Market Signals| Indicator | TRUE | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 69.57 | 57.62 |
| Support Level | $2.11 | $3.24 |
| Resistance Level | $2.17 | $3.80 |
| Average True Range (ATR) | 0.07 | 0.27 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 100.00 | 72.54 |
Price Performance
Historical ComparisonAbout TRUE TrueCar Inc.
TrueCar Inc is a data-driven online platform operating on common technology infrastructure, powered by proprietary data and analytics. It also customizes and operates its platform for affinity group marketing partners, including financial institutions like PenFed and American Express; membership-based organizations like Consumer Reports, AARP, Sam's Club, and AAA; and employee buying programs for large enterprises such as IBM and Walmart. The Company has one operating segment, with three distinct service offerings: Dealer products and services, OEM incentives, and other.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.